JP2011505414A5 - - Google Patents

Download PDF

Info

Publication number
JP2011505414A5
JP2011505414A5 JP2010536523A JP2010536523A JP2011505414A5 JP 2011505414 A5 JP2011505414 A5 JP 2011505414A5 JP 2010536523 A JP2010536523 A JP 2010536523A JP 2010536523 A JP2010536523 A JP 2010536523A JP 2011505414 A5 JP2011505414 A5 JP 2011505414A5
Authority
JP
Japan
Prior art keywords
peptide
composition
subject
item
factor viii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010536523A
Other languages
English (en)
Japanese (ja)
Other versions
JP5501245B2 (ja
JP2011505414A (ja
Filing date
Publication date
Priority claimed from GBGB0723712.6A external-priority patent/GB0723712D0/en
Application filed filed Critical
Publication of JP2011505414A publication Critical patent/JP2011505414A/ja
Publication of JP2011505414A5 publication Critical patent/JP2011505414A5/ja
Application granted granted Critical
Publication of JP5501245B2 publication Critical patent/JP5501245B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010536523A 2007-12-04 2008-12-03 Ｆｖｉｉｉペプチドおよび血友病を寛容化することにおけるその使用 Expired - Fee Related JP5501245B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0723712.6 2007-12-04
GBGB0723712.6A GB0723712D0 (en) 2007-12-04 2007-12-04 Peptides
PCT/GB2008/003996 WO2009071886A1 (en) 2007-12-04 2008-12-03 Fviii peptides and their use in tolerising haemophiliacs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014023217A Division JP6063402B2 (ja) 2007-12-04 2014-02-10 Ｆｖｉｉｉペプチドおよび血友病を寛容化することにおけるその使用

Publications (3)

Publication Number Publication Date
JP2011505414A JP2011505414A (ja) 2011-02-24
JP2011505414A5 true JP2011505414A5 (enExample) 2012-10-25
JP5501245B2 JP5501245B2 (ja) 2014-05-21

Family

ID=38982965

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010536523A Expired - Fee Related JP5501245B2 (ja) 2007-12-04 2008-12-03 Ｆｖｉｉｉペプチドおよび血友病を寛容化することにおけるその使用
JP2014023217A Expired - Fee Related JP6063402B2 (ja) 2007-12-04 2014-02-10 Ｆｖｉｉｉペプチドおよび血友病を寛容化することにおけるその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014023217A Expired - Fee Related JP6063402B2 (ja) 2007-12-04 2014-02-10 Ｆｖｉｉｉペプチドおよび血友病を寛容化することにおけるその使用

Country Status (25)

Country Link
US (1) US8445448B2 (enExample)
EP (1) EP2227488B3 (enExample)
JP (2) JP5501245B2 (enExample)
KR (1) KR101519840B1 (enExample)
CN (2) CN103709234B (enExample)
AU (1) AU2008332968B2 (enExample)
BR (1) BRPI0820143A2 (enExample)
CA (2) CA2707559C (enExample)
CY (1) CY1115168T1 (enExample)
DK (1) DK2227488T6 (enExample)
EA (1) EA019370B1 (enExample)
EC (1) ECSP10010327A (enExample)
ES (1) ES2458315T7 (enExample)
GB (1) GB0723712D0 (enExample)
HR (1) HRP20140344T4 (enExample)
IL (1) IL205780A (enExample)
MX (1) MX2010006084A (enExample)
MY (1) MY150995A (enExample)
NZ (1) NZ585217A (enExample)
PL (1) PL2227488T6 (enExample)
PT (1) PT2227488E (enExample)
SI (1) SI2227488T1 (enExample)
UA (1) UA101003C2 (enExample)
WO (1) WO2009071886A1 (enExample)
ZA (1) ZA201002997B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030062321A (ko) 2000-08-21 2003-07-23 아피토프 테크놀러지 (브리스톨) 리미티드 펩티드 선별 방법
GB0801513D0 (en) * 2008-01-28 2008-03-05 Circassia Ltd Peptides from factor VIII
US8329871B2 (en) * 2008-06-24 2012-12-11 Octapharma Ag Process of purifying coagulation factor VIII
GB0908515D0 (en) * 2009-05-18 2009-06-24 Apitope Technology Bristol Ltd Peptide
US20120135917A1 (en) * 2009-06-16 2012-05-31 Eisaku Yoshihara Anti-Gram Negative Bacteria Agent
PL3260132T3 (pl) * 2010-10-27 2022-08-08 Takeda Pharmaceutical Company Limited Peptydy fviii do wywoływania tolerancji immunologicznej oraz immunodiagnostyki
EA038705B1 (ru) 2012-01-12 2021-10-07 Биовератив Терапьютикс Инк. Способы снижения иммуногенности фактора свёртывания крови viii у пациентов, получающих лечение фактором viii
CN104903347B (zh) * 2012-11-12 2020-02-21 艾匹托普国际股份有限公司 肽
GB201314052D0 (en) 2013-08-06 2013-09-18 Apitope Int Nv Peptides
MX2018006789A (es) 2015-12-03 2019-02-13 Juno Therapeutics Inc Receptores quimericos modificados y composiciones y metodos relacionados.
CA3044838A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
US12077607B2 (en) * 2021-09-23 2024-09-03 University Of Utah Research Foundation Functional and therapeutic effects of PAR4 cleavage by cathepsin G

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990015615A1 (en) * 1989-06-20 1990-12-27 Scripps Clinic And Research Foundation The phospholipid binding domain of factor viii
US6132729A (en) * 1997-01-22 2000-10-17 Board Of Regents, The University Of Texas System Combined tissue factor and chemotherapeutic methods and compositions for coagulation and tumor treatment
KR20030062321A (ko) 2000-08-21 2003-07-23 아피토프 테크놀러지 (브리스톨) 리미티드 펩티드 선별 방법
US20040096456A1 (en) * 2000-12-01 2004-05-20 Conti-Fine Bianca M Method to treat hemophilia
PL362324A1 (en) * 2001-02-19 2004-10-18 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
AU2002312660A1 (en) * 2001-05-31 2002-12-16 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
MXPA04010061A (es) * 2002-04-18 2004-12-13 Merck Patent Gmbh Factor viii modificado.
CN102816241B (zh) * 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
WO2006003183A1 (de) 2004-07-02 2006-01-12 Alois Jungbauer Peptide zur blockierung von fviii-inhibitoren
IL229645A0 (en) * 2013-11-26 2014-03-31 Omrix Biopharmaceuticals Ltd A dry bandage containing thrombin and pectin

Similar Documents

Publication Publication Date Title
Lhuillier et al. Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control
Banik et al. Immunoepigenetics combination therapies: an overview of the role of HDACs in cancer immunotherapy
JP2012515778A5 (enExample)
US20170312334A1 (en) Methods and compositions for treating inflammatory disorders
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
CL2018000537A1 (es) Anticuerpo anti-factor d del complemento; polinucleótido codificante; vector que comprende dicho polinucleótido; célula húesped que comprende dicho vector; método de fabricación de anticuerpo; composición farmacéutica que lo comprende; uso del anticuerpo para tratar trastornos inflamatorios o trastornos oculares (divisional de cl 1001-2009).
Stone et al. Genomics of human fibrotic diseases: disordered wound healing response
Rizzacasa et al. LOX-1 and its splice variants: a new challenge for atherosclerosis and cancer-targeted therapies
CN112661838A (zh) 用于肺癌(包括非小细胞肺癌和其他癌症)免疫治疗的新型肽和肽组合物
ATE468409T1 (de) Identifizierung von oberflächen-assoziierten antigenen für die tumordiagnose und -therapie
AR083740A1 (es) Anticuerpos dkk1 (dickkopf-1) y metodos de uso
JP2017525336A5 (enExample)
JP2012527440A5 (enExample)
JP2015504299A5 (enExample)
JP2017511377A5 (enExample)
JP2015522264A5 (enExample)
JP2009540852A5 (enExample)
Nielsen et al. Toward personalized lymphoma immunotherapy: identification of common driver mutations recognized by patient CD8+ T cells
JP2019500057A (ja) ネオエピトープのウイルス送達のための改善された組成物および方法ならびにその使用
EP3615694A1 (en) Il-8, il-6, il-1b and tet2 and dnmt3a in atherosclerosis
Hassan et al. Microglia-mediated phagocytosis in Alzheimer’s disease: Mechanisms, heterogeneity, and therapeutic insights
JP2020502498A5 (enExample)
FI20011664A7 (fi) Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö
Turcot et al. Comparison of the dipeptidyl peptidase-4 gene methylation levels between severely obese subjects with and without the metabolic syndrome
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.